Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
(TSV:
NGEN
)
8.080
+0.260 (+3.32%)
Streaming Delayed Price
Updated: 3:59 PM EST, Jan 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
291,552
Open
8.490
Bid (Size)
7.970 (5)
Ask (Size)
8.200 (39)
Prev. Close
7.820
Today's Range
7.700 - 8.490
52wk Range
2.570 - 8.490
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
NervGen Pharma Begins Trading on Nasdaq Today
January 08, 2026
From
NervGen Pharma Corp.
Via
GlobeNewswire
NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury
June 02, 2025
From
NervGen Pharma Corp.
Via
GlobeNewswire
Performance
YTD
+1.9%
+1.9%
1 Month
+35.8%
+35.8%
3 Month
+73.8%
+73.8%
6 Month
+100.5%
+100.5%
1 Year
+165.8%
+165.8%
More News
Read More
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
March 14, 2025
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Sciences Investor Forum Agenda Announced for March 13th
March 12, 2025
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Science Investor Forum: Presentations Now Available for Online Viewing
June 23, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Science Investor Forum Agenda Announced for June 22nd
June 20, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
NervGen Pharma Announces Leadership Transition
September 22, 2022
Via
Newsfile
Encode Ideas, L.P. Announces the Initiation of Research Coverage on NervGen Pharma Corp.
September 13, 2021
Via
Newsfile
NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve University
July 28, 2022
From
NervGen Pharma Corp.
Via
Business Wire
NervGen Engages Vorticom Inc. to Provide Media Relations Services
June 25, 2021
Via
Newsfile
NervGen Pharma Enters into Research Agreement with Sylics to Study NVG-291 in Alzheimer's Disease Models
June 10, 2021
Via
Newsfile
NervGen Pharma Reports First Quarter 2021 Results
May 20, 2021
Via
Newsfile
NervGen Pharma Announces Closing of Overnight Marketed Equity Offering
May 12, 2021
Via
Newsfile
NervGen Pharma Grants Stock Options
May 07, 2021
Via
Newsfile
NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-291
May 06, 2021
Via
Newsfile
NervGen Pharma Corp. Announces Overnight Marketed Equity Offering
May 04, 2021
Via
Newsfile
NervGen Pharma Grants Stock Options
April 23, 2021
Via
Newsfile
NervGen Pharma Announces Appointment of Pharma Veteran Dr. Daniel Mikol as Chief Medical Officer
April 22, 2021
Via
Newsfile
NervGen Pharma Receives Ethics Approval to Initiate Phase 1 Clinical Trial for NVG-291
April 14, 2021
Via
Newsfile
NervGen Pharma Reports 2020 Year End Results
April 08, 2021
Via
Newsfile
Frequently Asked Questions
Is NGEN publicly traded?
Yes, NGEN is publicly traded.
What exchange does NGEN trade on?
NGEN trades on the Toronto Venture Stock Exchange
What is the ticker symbol for NGEN?
The ticker symbol for NGEN is NGEN on the Toronto Venture Stock Exchange
What is the current price of NGEN?
The current price of NGEN is 8.080
When was NGEN last traded?
The last trade of NGEN was at 01/08/26 03:59 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.